Rosalia Rina
Department of Health Sciences, College of Science, Health, Engineering and Education (SHEE), Murdoch University - Dubai Campus, Dubai, United Arab Emirates.
Drug Healthc Patient Saf. 2021 Jan 27;13:11-18. doi: 10.2147/DHPS.S272411. eCollection 2021.
A beta coronavirus was identified in Wuhan, China, in December 2019 and was named severe acute respiratory syndrome coronavirus-2. It spread globally at a rapid rate and killed innumerable people. The SARS-CoV-2 infection, also called coronavirus disease 2019, was declared a pandemic by WHO on March 11, 2020. The increasing number of SARS-CoV-2 related deaths is due to a number of reasons. A few antiviral, antimicrobial, and immune-based drugs have been repurposed for treatment as well as improvement of patient prognosis. These drugs are currently being studied in clinical trials conducted by the World Health Organization (WHO), National Institutes of Health (NIH), and other global health organizations to identify the agents that produce maximum positive patient outcomes and reduction in mortality rate. The aim of this article is to discuss the safety and efficacy of the repurposed drugs in SARS-CoV-2 infection based on currently available clinical evidence and to emphasize the importance of caution required whilst employing the international therapeutic guidelines. Also highlighted in this article are certain specific comorbid conditions, that either involve treatment with the repurposed drugs or have a direct impact of the virus in patients owing to their vulnerability.
2019年12月，在中国武汉发现了一种β冠状病毒，被命名为严重急性呼吸综合征冠状病毒2。它以极快的速度在全球传播，导致无数人死亡。2020年3月11日，世界卫生组织宣布严重急性呼吸综合征冠状病毒2感染（也称为2019冠状病毒病）为大流行病。与严重急性呼吸综合征冠状病毒2相关的死亡人数不断增加，原因是多方面的。一些抗病毒、抗菌和基于免疫的药物已被重新用于治疗以及改善患者预后。目前，世界卫生组织（WHO）、美国国立卫生研究院（NIH）和其他全球卫生组织正在进行临床试验，研究这些药物，以确定能产生最大积极患者结果并降低死亡率的药物。本文的目的是根据目前可得的临床证据，讨论重新利用的药物在严重急性呼吸综合征冠状病毒2感染中的安全性和有效性，并强调在采用国际治疗指南时谨慎的重要性。本文还强调了某些特定的合并症，这些合并症要么涉及使用重新利用的药物进行治疗，要么由于患者易感性而使病毒对患者产生直接影响。
